The PAK1-Stat3 Signaling Pathway Activates IL-6 Gene Transcription and Human Breast Cancer Stem Cell Formation (2019)

Peer-Reviewed Study · (Cancers 2019; see PubMed 31658701 for author list) · 2019

(Cancers 2019 et al., 2019: Breast cancer study using ivermectin as a PAK1 inactivator to show that PAK1/Stat3-driven IL-6 transcription drives cancer stem cell formation, and that inactivating PAK1 blocks mammosphere and CSC formation.

In this study, we found that p21-activated kinase (PAK1) inhibitor (Group I, PAK inhibitor, IPA-3) and inactivator (ivermectin) treatments inhibit cell proliferation and that tumor growth of PAK1-knockout cells in a mouse model is significantly reduced.

n/a (HTML full text)

(Cancers 2019 et al., 2019: Breast cancer study using ivermectin as a PAK1 inactivator to show that PAK1/Stat3-driven IL-6 transcription drives cancer stem cell formation, and that inactivating PAK1 blocks mammosphere and CSC formation. Study type: cell lines, mammospheres and mouse xenograft with PAK1-knockout cells. N: not stated in the abstract. Country: South Korea (Jeju National University). Dose: not stated in the abstract. Declared COI: 'The authors declare no conflicts of interest.' Comparator: IPA-3 PAK inhibitor, JAK2 inhibitor TG101209, PAK1-knockout cells. Links the CSC arm (C6) to the PAK1 arm (C3). Study type: animal.